Brokerages Set Urogen Pharma (NASDAQ:URGN) Target Price at $41.62

Shares of Urogen Pharma (NASDAQ:URGN) have earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $41.6250.

Several equities research analysts have weighed in on the company. UBS Group restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Guggenheim lifted their price objective on Urogen Pharma from $32.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research note on Friday, July 17th. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 target price on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, Oppenheimer lifted their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th.

Insider Buying and Selling at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares of the company’s stock, valued at approximately $4,790,520. The trade was a 7.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors have recently added to or reduced their stakes in the business. Hennion & Walsh Asset Management Inc. raised its stake in Urogen Pharma by 148.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 161,924 shares of the company’s stock worth $3,792,000 after acquiring an additional 96,741 shares in the last quarter. SG Americas Securities LLC boosted its stake in Urogen Pharma by 20.3% in the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after acquiring an additional 280,199 shares in the last quarter. Swiss National Bank purchased a new position in shares of Urogen Pharma during the first quarter worth about $1,399,000. Rice Hall James & Associates LLC grew its holdings in shares of Urogen Pharma by 8.8% during the fourth quarter. Rice Hall James & Associates LLC now owns 281,876 shares of the company’s stock worth $6,602,000 after purchasing an additional 22,733 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Urogen Pharma by 139.1% during the first quarter. ADAR1 Capital Management LLC now owns 395,459 shares of the company’s stock worth $7,110,000 after purchasing an additional 230,084 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $39.92 on Wednesday. Urogen Pharma has a fifty-two week low of $15.86 and a fifty-two week high of $43.93. The company has a 50 day moving average price of $35.39 and a 200 day moving average price of $26.61. The stock has a market capitalization of $1.94 billion, a P/E ratio of -14.52 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million for the quarter, compared to analyst estimates of $44.83 million. On average, research analysts forecast that Urogen Pharma will post -0.76 EPS for the current fiscal year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.